» Articles » PMID: 30444317

Injectable Biodegradable Chitosan-Alginate 3D Porous Gel Scaffold for MRNA Vaccine Delivery

Overview
Journal Macromol Biosci
Specialties Biochemistry
Biology
Date 2018 Nov 17
PMID 30444317
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

mRNA vaccines have proven to be more stable, effective, and specific than protein/peptide-based vaccines in stimulating both humoral and cellular immune response. However, mRNA's fast degradation rate and low-transfection efficiency in vivo impede its potential in vaccination. Recent research in gene delivery has focused on nonviral vaccine carriers and either implantable or injectable delivery systems to improve transgene expression in vivo. Here, an injectable chitosan-alginate gel scaffold for the local delivery of mRNA vaccines is reported. Gel scaffold biodegradation rates and biocompatibility are quantified. Scaffold-mediated mRNA in vivo transgene expression as well as ovalbumin antigen specific cellular and humoral immune responses are evaluated in vivo. Luciferase reporter protein expression resulting from mRNA lipoplex-loaded gel scaffolds is five times higher than systemic injection. Compared to systemic injections of naked mRNA or mRNA:lipoplexes, elevated levels of T cell proliferation and IFN-γ secretion are seen with in vivo scaffold-mediated mRNA lipoplex delivery. Furthermore, a humoral response (ovalbumin antigen specific IgG levels) is observed as early as week 1 for scaffold-mediated mRNA lipoplex delivery, while protein-based immunization did not elicit IgG production until 2 weeks post-injection. Results suggest that injectable scaffold mRNA vaccine delivery maybe a viable alternative to traditional nucleic acid immunization methods.

Citing Articles

Beyond Needles: Immunomodulatory Hydrogel-Guided Vaccine Delivery Systems.

Rana M, Demirkaya C, De la Hoz Siegler H Gels. 2025; 11(1).

PMID: 39851978 PMC: 11764567. DOI: 10.3390/gels11010007.


Alginate-Chitosan Biodegradable and Biocompatible Based Hydrogel for Breast Cancer Immunotherapy and Diagnosis: A Comprehensive Review.

Patra P, Upadhyay T, Alshammari N, Saeed M, Kesari K ACS Appl Bio Mater. 2024; 7(6):3515-3534.

PMID: 38787337 PMC: 11190989. DOI: 10.1021/acsabm.3c00984.


A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection.

Mayer D, Nelson M, Andriyanova D, Filler R, Okten A, Antao O J Control Release. 2024; 370:570-582.

PMID: 38734312 PMC: 11665867. DOI: 10.1016/j.jconrel.2024.05.008.


Improved Humoral Immunity and Protection against Influenza Virus Infection with a 3d Porous Biomaterial Vaccine.

Miwa H, Antao O, Kelly-Scumpia K, Baghdasarian S, Mayer D, Shang L Adv Sci (Weinh). 2023; 10(31):e2302248.

PMID: 37750461 PMC: 10625058. DOI: 10.1002/advs.202302248.


Emerging Progress of RNA-Based Antitumor Therapeutics.

Fu J, Dong H, Wu J, Jin Y Int J Biol Sci. 2023; 19(10):3159-3183.

PMID: 37416764 PMC: 10321292. DOI: 10.7150/ijbs.83732.


References
1.
Lungwitz U, Breunig M, Blunk T, Gopferich A . Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005; 60(2):247-66. DOI: 10.1016/j.ejpb.2004.11.011. View

2.
Geall A, Mandl C, Ulmer J . RNA: the new revolution in nucleic acid vaccines. Semin Immunol. 2013; 25(2):152-9. DOI: 10.1016/j.smim.2013.05.001. View

3.
Al-Dosari M, Gao X . Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 2009; 11(4):671-81. PMC: 2782077. DOI: 10.1208/s12248-009-9143-y. View

4.
Goldman C, Soroceanu L, Smith N, Gillespie G, Shaw W, Burgess S . In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer. Nat Biotechnol. 1997; 15(5):462-6. DOI: 10.1038/nbt0597-462. View

5.
Tsang K, Cheung M, Chan D, Cheah K . The developmental roles of the extracellular matrix: beyond structure to regulation. Cell Tissue Res. 2009; 339(1):93-110. DOI: 10.1007/s00441-009-0893-8. View